Compare PRG & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | VIR |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2020 | 2019 |
| Metric | PRG | VIR |
|---|---|---|
| Price | $30.46 | $11.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $52.00 | $21.00 |
| AVG Volume (30 Days) | 663.6K | ★ 1.9M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,409,223,000.00 | $68,556,000.00 |
| Revenue This Year | $27.00 | $257.66 |
| Revenue Next Year | $7.67 | N/A |
| P/E Ratio | $17.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.80 | $4.82 |
| 52 Week High | $47.73 | $11.94 |
| Indicator | PRG | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 26.82 | 59.75 |
| Support Level | $28.97 | $8.43 |
| Resistance Level | $33.81 | $11.77 |
| Average True Range (ATR) | 1.21 | 0.65 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 22.41 | 84.43 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.